Page 54 - TD-4-1

Tumor Discovery WDR4 in cancer

diabetic infections. Int J Biol Macromol. 2025;296:139685. doi: 10.1016/j.jds.2023.06.014
doi: 10.1016/j.ijbiomac.2025.139685 61. Poryazova E, Serteva D, Markov D, Chonov V, Markov G.
Expression of snail and twist compared with clinical and
52. Liang C, Liu J, Jiang M, Zhu Y, Dong P. The advancement of
targeted regulation of hepatic stellate cells using Traditional pathological parameters in patients with gastric cancer. Folia
Chinese medicine for the treatment of liver fibrosis. Med (Plovdiv). 2023;65(3):393-398.
J Ethnopharmacol. 2025;341:119298. doi: 10.3897/folmed.65.e84132
doi: 10.1016/j.jep.2024.119298 62. Pek JH, Quah LJJ, Teng KPD, Yeo YWM, Lee CYJ.
Developing the disaster medical responderndecourse
53. Wang Y, Xiong G, Cai W, Tao Q. METTL1 facilitates
ameloblastoma invasive growth via MAPK signaling in Singapore. Western Pac Surveill Response J.
pathway. Gene. 2024;905:148234. 2023;14(6 Spec edition):1-6.
doi: 10.5365/wpsar.2023.14.6.1009
doi: 10.1016/j.gene.2024.148234
63. Chen B, Jiang W, Huang Y, et al. N -methylguanosine tRNA
7
54. Wang M, Zheng Y, Hao Q, et al. Hypoxic BMSC-derived
exosomal miR-210-3p promotes progression of triple- modification promotes tumorigenesis and chemoresistance
negative breast cancer cells via NFIX-Wnt/beta-catenin through WNT/ters in patients with gastric cancer. noma.
signaling axis. J Transl Med. 2025;23(1):39. cinOncogene. 2022;41(15):2239-2253.
doi: 10.1186/s12967-024-05947-5 doi: 10.1038/s41388-022-02250-9
55. Utpal BK, Roy SC, Zehravi M, et al. Polyphenols as 64. Sabbah DA, Hajjo R, Sweidan K. Review on epidermal
Wnt/M, i M, -5pathway modulators: A promising strategy growth factor receptor (EGFR) structure, signaling pathways,
in clinical neurodegeneration. Anim Model Exp Med. interactions, and recent updates of EGFR inhibitors. Curr
2025. Top Med Chem. 2020;20(10):815-834.
doi: 10.1002/ame2.12525 doi: 10.2174/1568026620666200303123102
56. Singhai H, Raikwar S, Rathee S, Jain SK. Emerging 65. Talukdar S, Emdad L, Das SK, Fisher PB. EGFR: An essential
combinatorial drug delivery strategies for breast cancer: receptor tyrosine kinase-regulator of cancer stem cells. Adv
A comprehensive review. Curr Drug Targets. 2025. Cancer Res. 2020;147:161-188.
doi: 10.2174/0113894501352081241211090911 doi: 10.1016/bs.acr.2020.04.003
57. Ye TT, Chen WH, Pei J, Jia YX, Wu HY. Expression and 66. Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR
clinical significance of NEK2 and EMT related molecules in inhibitors: Critical updates. Mini Rev Med Chem.
oral squamous cell carcinoma. Shanghai Kou Qiang Yi Xue. 2016;16(14):1134-1166.
2023;32(6):640-644. doi: 10.2174/1389557516666160321114917
doi: 10.19439/j.sjos.2023.06.014 67. Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A review in
58. Ye F, Xie L, Liang L, et al. Mechanisms and therapeutic hepatocellular carcinoma. Drugs. 2019;79(6):665-674.
strategies to combat the recurrence and progression of doi: 10.1007/s40265-019-01116-x
hepatocellular carcinoma after thermal ablation. J Interv 7
Med. 2023;6(4):160-169. 68. Ying X, Liu B, Yuan Z, et al. METTL1-m G-EGFR/EFEMP1
axis promotes the bladder cancer development. Clin Transl
doi: 10.1016/j.jimed.2023.10.004 Med. 2021;11(12):e675.
59. Yang HW, Chun-Yu Ho D, Liao HY, et al. Resveratrol doi: 10.1002/ctm2.675
inhibits arecoline-induced fibrotic properties of buccal
mucosal fibroblasts via miR-200a activation. J Dent Sci. 69. Nai F, Flores Espinoza MP, Invernizzi A, et al. Small-
2024;19(2):1028-1035. Molecule Inhibitors of the m7G-RNA Writer METTL1. ACS
Bio Med Chem Au. 2024;4(2):100-110.
doi: 10.1016/j.jds.2023.06.027
doi: 10.1021/acsbiomedchemau.3c00030
60. Wang R, Zhu F, Gao G, et al. B-cell specific Moloney murine
leukemia virus insertion site 1 contributes to invasion, 70. Zhao W. Ling-Ling Chen: RNA has its own features; don’t
metastasis, and poor prognosis in salivary adenoid cystic study it as a protein. Natl Sci Rev. 2024;11(2):nwad287.
carcinoma. J Dent Sci. 2024;19(1):21-31. doi: 10.1093/nsr/nwad287

Volume 4 Issue 1 (2025) 46 doi: 10.36922/td.5830